Top ASX 200 Blue Chip Shares to Consider in December - Kalkine Media

December 01, 2023 05:23 PM AEDT | By Team Kalkine Media
Follow us on Google News:

As investors navigate the market landscape in December, three ASX 200 blue-chip shares have emerged as potential additions to portfolios, drawing positive recommendations from brokers. This highlights the ongoing interest and potential opportunities within ASX blue-chip stocks, where investor sentiment and broker recommendations play a crucial role in shaping investment decisions. 

  1. Endeavour Group Ltd (ASX: EDV)
  • Business Profile: Endeavour Group is a prominent player in the drinks industry, boasting well-known brands like BWS and Dan Murphy's, coupled with an extensive network of hotels. 
  • Broker Recommendation: Goldman Sachs has identified Endeavour as an appealing ASX 200 blue-chip share to consider for investment. The broker underlines the company's market leadership and optimistic outlook, emphasizing its attractive valuation compared to peers in the Staples sector. 
  • Valuation and Target Price: Goldman Sachs maintains a conviction buy rating on Endeavour's shares with a target price of $6.40. 
  1. Macquarie Group Ltd (ASX: MQG)
  • Business Profile: Macquarie Group, an investment bank with diverse operations, stands out for its exposure to long-term structural growth areas, including infrastructure and renewables. 
  • Broker Recommendation: Morgans holds a positive view on Macquarie, citing its exposure to enduring growth sectors and potential benefits from recent market volatility through its trading businesses. The bank is also making strides in gaining market share in Australian mortgages. 
  • Valuation and Target Price: Morgans assigns an add rating to Macquarie Group's shares with a target price of $182.80. 
  1. ResMed Inc. (ASX: RMD)
  • Business Profile: ResMed, a medical device company focusing on sleep treatment, offers a portfolio comprising leading hardware and digital solutions. 
  • Broker Recommendation: Goldman Sachs sees ResMed favorably, interpreting recent share price weakness as a strategic buying opportunity. The broker perceives a favorable risk/reward scenario, deeming the valuation attractive and maintaining a buy rating on the shares. 
  • Valuation and Target Price: Goldman Sachs upholds a buy rating on ResMed's shares with a target price of $32.00. 

While these ASX 200 blue-chip shares have received positive endorsements from brokers, prudent investors should conduct thorough due diligence. Individual research, aligned with specific investment goals and risk tolerance, remains crucial in making informed decisions in the dynamic market environment. 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.



Top ASX Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK